Sulfonylurea Interactions

Coadministration may increase risk of hypoglycemia, potentially requiring lower doses of the insulin secretagogue.

Source: NLP:alogliptin and metformin hydrochloride

Risk of hypoglycemia may be increased when dapagliflozin is used concomitantly with sulfonylurea insulin secretagogues. Concomitant use may require lower doses to reduce hypoglycemia risk.

Source: NLP:dapagliflozin

Insulin secretagogue that increases hypoglycemia risk when combined with XIGDUO XR; may require lower doses.

Source: NLP:dapagliflozin and metformin hydrochloride

Risk of hypoglycemia is increased when combined with empagliflozin; lower sulfonylurea doses may be needed.

Source: NLP:empagliflozin

Risk of hypoglycemia is increased when GLYXAMBI is combined with sulfonylureas (insulin secretagogues). May require lower dosages.

Source: NLP:empagliflozin and linagliptin

Concomitant use increases hypoglycemia risk; sulfonylurea dosage reduction may be needed.

Source: NLP:empagliflozin, linagliptin, metformin hydrochloride

Insulin secretagogues increase hypoglycemia risk when combined with linagliptin and metformin. Sulfonylurea dosage may require reduction.

Source: NLP:linagliptin and metformin hydrochloride

Liraglutide stimulates insulin release and increases risk of hypoglycemia, including severe hypoglycemia, when combined with sulfonylureas. Consider reducing sulfonylurea dose.

Source: NLP:liraglutide

Insulin secretagogue that when combined with metformin may increase risk of hypoglycemia.

Source: NLP:metformin hydrochloride

Insulin secretagogue that increases hypoglycemia risk when combined with ZITUVIMET XR; may require dose reduction.

Source: NLP:sitagliptin and metformin hydrochloride

Coadministration may increase hypoglycemia risk. Lower dosages of sulfonylurea may be required when used with alogliptin.

Source: NLP:alogliptin

Concomitant use increases hypoglycemia risk; sulfonylurea dosage may require reduction.

Source: NLP:empagliflozin and metformin hydrochloride

Insulin secretagogue that increases risk of hypoglycemia when combined with SYNJARDY or SYNJARDY XR; dose reduction may be needed.

Source: NLP:empagliflozin, metformin hydrochloride

Coadministration increases risk of hypoglycemia. May require lower dosages of sulfonylurea to reduce hypoglycemia risk.

Source: NLP:linagliptin

Insulin secretagogue that increases hypoglycemia risk when coadministered with metformin.

Source: NLP:metformin

Insulin secretagogue that with metformin may increase risk of hypoglycemia. Patient may require lower doses of insulin secretagogue.

Source: NLP:metformin er 500 mg

Insulin secretagogue that increases hypoglycemia risk when combined with metformin; may require dose adjustment.

Source: NLP:metformin hydrochloride extended-release tablets

Insulin secretagogue that when combined with metformin may increase risk of hypoglycemia.

Source: NLP:metformin hydrochloride tablet

When initiating FOUNDAYO, consider reducing the dose of concomitantly administered sulfonylureas due to potential additive effects on glucose lowering.

Source: NLP:orforglipron

Concomitant use may increase the risk of photosensitivity reaction. Avoid concomitant use with other photosensitizing agents.

Source: NLP:porfimer sodium

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class.

Source: NLP:salsalate

Coadministration may require lower doses of sulfonylurea to reduce the risk of hypoglycemia.

Source: NLP:sitagliptin

Potentiation of the action of sulfonylurea hypoglycemic agents may be noted, possibly due to displacement from albumin or pharmacodynamic mechanism.

Source: NLP:sulfadiazine

Other photosensitizing agents that could increase the potential for skin photosensitivity reactions.

Source: NLP:verteporfin for injection